查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405747

美國前列腺癌症醫學診斷市場規模、佔有率、趨勢分析報告：按產品類型、PET 產品和細分市場預測，2023-2030 年

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report By Type (SPECT, PET), By PET Product (F-18, SR-82/RB-82), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國前列腺癌症醫學診斷市場的成長和趨勢：

Grand View Research最新報告顯示，到2030年，美國前列腺癌核醫診斷市場規模預計將達到1.5397億美元。

2023年至2030年的複合年成長率預計為9.2%。據美國癌症協會（ACS）稱，2019年美國將有174,650例前列腺癌新發病例和31,620例前列腺癌死亡病例。

用於改善目標疾病檢測的新型放射性藥物的市場開拓預計將加速市場成長。例如，正在使用 68Ga 和 18F 放射性同位素開發針對前列腺特異性膜抗原 (PSMA) 的新型顯影劑。此外，研究人員進行了大量研究，以開發用於正子斷層掃描 (PET) 的新型診斷劑，與現有試劑相比，其效率更高。例如，89Zr-huJ591 是一種用於 PET 檢測前列腺癌的顯影劑。該藥物正處於 I/II階段臨床試驗，很可能在預測期內上市。

對準確診斷方法的需求不斷成長預計將推動美國前列腺癌症核醫學診斷市場的成長。 PET 通常與 MRI 和電腦斷層掃描相結合，以提高惡性的診斷準確性。因此，研究人員正在研究 PET/MRI 以改善患者的治療結果。例如，2018年12月，《核子醫學雜誌》發表的一項研究表明，68Ga-PSMA-11 PET/MRI在檢測目標腫瘤方面具有優勢。

各種非營利組織資助研究，幫助引入新的腫瘤診斷顯像劑。前列腺癌基金會是領先組織之一，20 多年來一直資助各種 PSMA-PET 影像開發研究。此類資助機構和計劃的存在預計將在預測期內促進市場成長。

主要市場參與者正在採取策略性措施來加強其在市場上的影響力。例如，2018年2月，Axumin（氟昔洛韋F18）注射液被涵蓋NCCN（美國綜合癌症網路）前列腺癌腫瘤學臨床實務指引。臨床醫生和醫療保健提供者使用的更新指南現在指出，在復發或晚期前列腺癌患者的臨床檢查中應考慮注射氟西洛素 F18 進行 PET/MRI 或 PET/CT。

美國前列腺癌核醫學診斷市場報告亮點：

  • 2022 年，PET 由於在分子層面上提高了生化和生理過程的靈敏度和量化，推動了美國前列腺癌症核醫學診斷市場。
  • SR-82/RB-82 領域預計在預測期內複合年成長率為 9.9%。
  • Fluorine-18 將在 2022 年引領 PET 產品，具有更高的診斷效能、更高品質的影像和更短的擷取時間。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國前列腺癌症核醫診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 美國前列腺癌症醫學診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國前列腺癌症核醫診斷市場：類型估計與趨勢分析

  • 美國前列腺癌症核醫學診斷市場：要點
  • 美國前列腺癌症核醫學診斷市場：2022 年和 2030 年類型變化和市場佔有率分析
  • SPECT
  • PET

第5章美國前列腺癌症醫學診斷市場：PET產品預估及趨勢分析

  • 美國前列腺癌症核醫學診斷市場：要點
  • 美國前列腺癌症核醫學診斷市場：2022年和2030年PET產品趨勢和市場佔有率分析
  • F-18
  • SR-82/RB-82
  • 其他

第6章競爭形勢

  • 主要參與者的最新進展和影響分析
  • 公司/競爭分類
    • Blue Earth Diagnostics
    • Siemens Healthcare Private Limited
    • Cardinal Health
    • CURIUM PHARMA
    • Lantheus
    • Jubilant Draximage Radiopharmacies, Inc.
    • NCM-USA LLC
    • Telix Pharmaceuticals Limited
    • ARICEUM THERAPEUTICS
    • Novartis AG
    • Life Molecular Imaging
Product Code: GVR-3-68038-584-7

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Growth & Trends:

The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach USD 153.97 million by 2030, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 9.2% from 2023 to 2030. According to the American Cancer Society (ACS), in 2019, 174,650 new cases and 31,620 deaths caused by caused by prostate cancer are expected to be recorded in U.S. Such high prevalence of the disease is expected to drive the market growth.

Development of novel radiopharmaceuticals to improve the detection of the target disease is anticipated to accelerate the market growth. For instance, new imaging agents targeting Prostate-specific Membrane Antigen (PSMA) are being developed using 68Ga and 18F radioisotopes. In addition, numerous studies are being performed by researchers to develop new diagnostic agents for Positron Emission Tomography (PET) with higher efficiency as compared to the existing agents. For instance, 89Zr-huJ591 is an imaging agent used with PET for the detection of prostate cancer. This agent is in phase I/II of clinical trials, and is likely to get launched over the forecast period.

Growing demand for accurate diagnostic methods is estimated to fuel growth of the U.S. prostate cancer nuclear medicine diagnostics market. PET is commonly integrated with MRI and CT scan to enhance accuracy of diagnosis in malignancies. Therefore, researchers are conducting studies on PET/MRI to improve patient outcomes. For instance, in December 2018, a study was published in The Journal of Nuclear Medicine stating that 68Ga-PSMA-11 PET/MRI can be advantageous in detecting the target tumor.

Various non-profit organizations fund research studies to help introduce new imaging agents for the diagnosis of tumors. The Prostate Cancer Foundation is one of the major organizations that has been funding different studies for the development of PSMA-PET imaging for over 20 years. Presence of such funding organizations and programs is expected to boost the market growth during the forecast period.

Key market players have undertaken strategic initiatives to strengthen their market presence. For instance, in February 2018, Axumin (fluciclovine F 18) injection was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer. The updated guidelines used by clinicians and healthcare providers stated that fluciclovine F 18 for PET/MRI or PET/CT is considered in the clinical workup of patients with recurrent or advanced prostate cancer.

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Report Highlights:

  • In 2022, PET led the U.S. prostate cancer nuclear medicine diagnostics market owing to increased sensitivity and quantification of biochemical and physiological processes at a molecular level
  • The SR-82/RB-82 segment is expected to expand at a CAGR of 9.9% over the forecast period
  • Fluorine-18 led the PET products in 2022 owing to higher diagnostic performance and high-quality images, with a shorter acquisition time

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. PET product
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. PET product
  • 2.3. Competitive Insights

Chapter 3. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
  • 4.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. SPECT
    • 4.3.1. SPECT market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. PET
    • 4.4.1. PET market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Estimates & Trend Analysis

  • 5.1. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Key Takeaways
  • 5.2. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Movement & Market Share Analysis, 2022 & 2030
  • 5.3. F-18
    • 5.3.1. F-18 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. SR-82/RB-82
    • 5.4.1. SR-82/RB-82 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Blue Earth Diagnostics
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Siemens Healthcare Private Limited
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Cardinal Health
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. CURIUM PHARMA
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Lantheus
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Jubilant Draximage Radiopharmacies, Inc.
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. NCM-USA LLC
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. Telix Pharmaceuticals Limited
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. ARICEUM THERAPEUTICS
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Novartis AG
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Life Molecular Imaging
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. prostate cancer nuclear medicine diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. prostate cancer nuclear medicine diagnostics market, by PET product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 U.S. prostate cancer nuclear medicine diagnostics: market outlook
  • Fig. 8 U.S. prostate cancer nuclear medicine diagnostics market: competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 U.S. prostate cancer nuclear medicine diagnostics market driver impact
  • Fig. 13 U.S. prostate cancer nuclear medicine diagnostics market restraint impact
  • Fig. 14 U.S. prostate cancer nuclear medicine diagnostics market strategic initiatives analysis
  • Fig. 15 U.S. prostate cancer nuclear medicine diagnostics market: Type movement analysis
  • Fig. 16 U.S. prostate cancer nuclear medicine diagnostics market: Type outlook and key takeaways
  • Fig. 17 SPECT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 PET market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. prostate cancer nuclear medicine diagnostics market: PET product movement analysis
  • Fig. 20 U.S. prostate cancer nuclear medicine diagnostics market: PET product outlook and key takeaways
  • Fig. 21 F-18 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 SR-82/RB-82 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)